But, extramedullary relapse of acute lymphoblastic leukemia (ALL) in the kidney after allogeneic stem cell transplantation (allo-SCT) is rare after either bone marrow transplantation or chemotherapy. In adult patient cohorts isolated or combined extramedullary relapse after allo-HSCT is associated with a better outcome than medullary relapse. [3] [4] Also, extramedullary versus medullary relapse seems to be favoured by chronic graft versus host disease and a long time interval between transplantation and relapse. 4 Isolated renal relapse after allogeneic peripheral hematopoietic stem cell transplantation (allo-PHSCT) in adult with Ph + acute lymphoblastic leukemia (ALL) is a rare condition. Generally, in ALL, the sites most frequently affected by extramedullary relapse are the central nervous system (CNS) and the testicles. There are single reports on relapses affecting abdominal lymph nodes, bones, thoracic wall, mediastinum, orbit/ upper eyelid, retro-orbital tissue, iris, heart and breast. [5] [6] [7] [8] [9] [10] [11] [12] [13] We, herein, report a case with relapsed Ph + B-precursor ALL, who underwent allo-PHSCT from HLA-identical siblings and suffered a histopathologically proven isolated bilateral renal relapse 2 years post alloHSCT.
CASE REPORT
A 45-year old male patient was diagnosed Ph+ pre-B-ALL in August 2005. On admission, laboratory investigations showed a total leukocyte count of 15.9 x 10 9 L-1 (differential blood count: neutrophils 20%, lymphocytes 12%, monocytes 3% and blasts 65%), hemoglobin 7.4 g dL-1, platelet count 50 x 10 9 L-1, lactate dehydrogenase of 1530 (N, 250-480). A bone marrow aspirate biopsy is performed which revealed TdT, CD19 and CD20 positive acute lymphoblastic leukemic infiltration of the marrow. A flow cytometric investigation showed that CD19, CD20, CD22, CD45, HLA-DR and TDT positive. Conventional cytogenetic and PCR analysis for t(9;22) gene product was positive.
Following the diagnosis of ALL, combination chemotherapy using high dose cytarabine and methotrexate has been initiated. The patient's disease did not respond to one cycle high dose cytarabine and methotrexate chemotherapy at the time of diagnosis. Complete remission was obtained with the hyperC-VAD (cyclophosphamide, vincristine, adriamycin and dexamethasone) combination chemotherapy. Eight courses consecutive high dose cytarabine-methotrexate and hyperCVAD were received. He relapsed in the bone marrow two months after chemotherapy and a second complete remission was obtained with the ALL-CALGB (cyclophosphamide, L-asparaginase, vincristine, daunorubicine and dexamethasone) combination chemotherapy and imatinib mesylate. He underwent first allogeneic matched-sibling peripheral blood stem cell transplantation (allo-PBSCT) in April 2006, during his first complete remission. Busulfan 0.8 mg/kg every 6 h for 8 doses, fludarabine 30 mg/m 2 /day for 6 days and antithymocyte globulin 2.5 mg/kg/day for 4 days were used as the reduced intensity conditioning regimen. The patient received GVHD prophylaxis consisting of cyclosporine A (CsA) 5 µg/kg/day by continuous intravenous infusion starting on day -2 and switched to the p.o. formulation the patient was able to tolerate medication p.o. and stopped after 100 days (absence of GVHD). And patient received methotexate at a dose of 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3 and +6 and +11 post transplant. The patient had no any acute or chronic graft-versus-host disease (GVHD). Bone marrow examinations 1, 3, 5, 6, 7, 8, 10, 12, and 14 months after HSCT showed complete remission morphologically, by flow cytometry and had complete donor chimaerism.
He was admitted with a renal failure and massive bilateral pleural effusion, two years after his first allo-PBSCT. Laboratory evaluation revealed a blood urea nitrogen level of 30 mg/dl and a serum creatinine level of 2.9 mg/dl. Five days later, the patient's serum creatinine level had increased to 5.5 mg/dl, and one week after initial presentation he was admitted to hospital for evaluation of acute renal failure. An ultrasound of his kidneys revealed marked bilateral renal enlargement with echogenic parenchyma. The right kidney measured 16 x 9 x 8.5 cm with 29 mm cortical thickness, and the left kidney measured 18 x 9.5 x 9 cm with 30 mm cortical thickness. A CT scan of the thorax showed bilaterally pleural effusion (7 cm) and abdomen also showed 20 x 8 mm aortico-caval intra-abdominal lymphadenopathy. Biopsy revealed dense interstitial infiltration of renal tissue by malignant lymphoid cells. They had small amounts of amphophilic cytoplasm and contained large nuclei with small nucleoli. Mitotic figures were numerous. Immunohistochemistry indicated precursor B cell phenotype with diffuse expression of CD20 and TdT (terminal deoxynucleotidyl transferase) in the neoplasm. The neoplastic cells were also positive for CD79a and CD10, but negative for CD3. The glomeruli were normal microscopically and negative with immunofluorescence. A bone marrow biopsy was normacellular. Bone marrow cells were shown to be of 98% of donor origin. The pleural effusion was infiltrated atypical lymphoid cells, and flow cytometric studies of pleural effusion showed a population of T and B lymphoblasts that expressed CD3, CD5, CD7, CD19, CD20 and HLA-DR. Philadelphia chromosome and bcr-abl were negative by cytogenetics and by molecular biological analysis, respectively. Chimaerism analysis showed complete chimaerism (98% donor type) at time of extramedullary relapse.
The acute renal failure was attributed to renal leukemic infiltration, the patients was given allopurinol for hyperuricemia and hydrated with alkalized intravenous fluids. Daily hemodialysis was initiated and was performed over three consecutive days. He was then started on a dasatinib consisted of 2 x 70 mg/day. Unfortunately the patient died of sepsis.
DISCUSSION
Isolated renal relapse after allogeneic peripheral hematopoietic stem cell transplantation (allo-PBSCT) in adults with acute lymphoblastic leukemia (ALL) is a rare condition. Extramedullary relapse of acute leukemias following allo-PBSCT is common in adult patients with rates of extramedullary involvement documented in 40-50% of cases. 3 The studies shown that isolated or combined extramedullary relapse is better outcome than medullary relapse. [3] [4] The mostfrequent sites of ALL involvement are skin, bone, soft tissue, lymph nodes, ovaries, retroperitoneum, tonsillar primary tumor, and mediastinum and biopsy is important for the diagnosis. Tumor infiltration of the kidney may occur, but accounts for renal insufficiency in only 1% of patients.
14 Most isolated extramedullary relapses after allo-PBSCT for ALL occur in the central nervous system (CNS) and the testicles, while relapses to other localizations are exceedingly rare. A different pattern of relapse has been observed after allogeneic BMT for patients with leukemia. Compared with treatment using conventional chemotherapy alone, isolated extra-medullary relapse of disease appears to be seen more commonly after allogeneic BMT. Isolated extramedullary relapse of acute lymphoblastic leukaemia (ALL) with sparing of the marrow after allogeneic bone marrow transp- lantation (BMT) is a rare occurrence, and the mechanisms underlying the selective involvement of extramedullary sites remain undefined. In the literature, the possible mechanisms associated that the leukaemic cells are resistant to chemotherapy or a stronger putative graft-versus-leukaemia effect in the marrow as compared with peripheral tissues. 5 Acute renal failure is unusual at the presentation of acute leukemia, and renal dysfunction more commonly occurs as a consequence of treatment for the leukemia.
1 Several factors may disturb renal function in leukemia patients that are nephrotoxicity, metabolic changes arising from chemotherapy, radiotherapy, infections, treatment with nephrotoxic antibiotics, intravascular coagulopathy and infiltration of kidneys with leukemic cells. [15] [16] [17] [18] [19] Acute renal failure due to leukemic cell infiltration into the kidney is rare in acute lymphoblastic leukemia after allogeneic-SCT, and this phenomenon might be related to kidney's role in embryonic hematopoiesis through the aorta-gonad-mesonephrons region. [20] [21] Tumor infiltration into the kidneys can occur, yet this accounts for renal insufficiency in only 1% of patients. 22 All of those relapses are associated with significant morbidity and mortality. Most relapses occur within the first 6-12 months, although disease-free survival curves do not begin to plateau until 24 months post-transplant.
The literature provides a significant decrease in post bone marrow transplantation nephropathy in adults with increasing shielding of the kidney. [23] [24] Because of this condition, they recommend renal shielding when doses higher than 10 Gy are applied. Although, Borg et al. demonstrated that a dose of 12 Gy at 2 Gy/fraction resulted in only 1 case of radiation nephritis in the 59 patients studied 24 months after the completion of TBI and BMT. And renal shielding was not used. Our patient did not receive TBI for conditioning regimen. The presence of graft-versushost disease has been shown to favour extramedullary relapse over medullary relapse. 4 In our patient no signs of acute and chronic graft-versus-host disease was observed prior to nor at the time of extramedullary relapse.
A potential mechanism in the trafficking of leukaemia cells is the interaction of the chemokine receptor CXCR4, which is expressed on ALL cells, and its ligand stromal cell-derived factor-1 (SDF-1), produced by stromal cells in bone marrow and extramedullary organs. 25 As high expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in ALL, Crazzolara et al. suggest that CXCR4 and its ligand play an essential role in extramedullary invasion. 25 We describe a rare presentation of extra-medullary relapse in an adult with Philadelphia chromosomepositive acute lymphoblastic leukemia who had undergone allogeneic bone marrow transplantation after first remission. In spite of enduring bone marrow remission, the patient experienced a local relapse in the kidneys within 2 years of the transplant. Extramedullary recurrences following allo-SCT for ALL usually occur in the 'sequestered sites', i.e. the testis and central nervous system. 3 The nervous system and testis are known as 'sanctuary' sites for chemotherapy, because anti-cancer drugs do not usually penetrate into these organs. These relapses usually have a poor prognosis. In these patients effective treatment has not been defined and the GVL effect may be of little value for these lesions. 26 The majority of relapses occur in the bone marrow. Nakayama et al. described isolated renal relapse after bone marrow transplantation in childhood leukemia in 1992. This is the first case in the adult patient whom had no evidence of leukemia on his marrow and 98% full-donor chimerism while he had Ph+ ALL relapse in his kidneys. Due to the low incidence of localized extramedullary relapses, therapeutic strategies for these complications are not yet defined. GVL effect may be stronger in the marrow than in peripheral tissues. The prognosis is poor in general, but prolonged survival has been observed in some of these patients. With the preservation of donor's hematopoiesis in the recipient's marrow, the use of intensive chemotherapy followed by donor lymphocyte or stem cell re-infusion is a promising option.
